Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770045 | 0.90 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11293751 | 0.90 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1011493 | 0.89 | RAF1 (0.49) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL770136 | 0.87 | RAF1 (0.46) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL769541 | 0.87 | RAF1 (0.64) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1015499 | 0.85 | RAF1 (0.52) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1012213 | 0.83 | RAF1 (0.48) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1015351 | 0.82 | RAF1 (0.50) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11966207 | 0.82 | RAF1 (0.47) | RAF1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4903102 | 0.82 | RAF1 (0.48) | RAF1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| EP-2358725-A1 | Imidazolothiazole compounds as modulators of protein kinase | Ambit Biosciences Corporation (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GRK2, GRK3, GRK4 | RAF1 127/4885MAPK13 291/4885MAPK12 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.